Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06483100 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Name: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance — clinical trial record (NCT06483100)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorWashington University School of Medicine

Started2024-12-20

View on ClinicalTrials.gov ↗

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.

Amendment history 2 changes detected by DataLookout

2026-08-07

Primary completion pushed: 2031-12-31 → 2032-06-30

2026-08-07

Completion pushed: 2031-12-31 → 2032-06-30

Trial Details

NCT Number	NCT06483100
Lead Sponsor	Washington University School of Medicine Collaborators: National Comprehensive Cancer Network, Pfizer
Conditions	Multiple Myeloma
Enrollment	65 participants
Start Date	2024-12-20
Primary Completion	2032-06-30 (estimated)
Study Completion	2032-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-06